Chinese Vitamin C Price-Fixing Case Could Alter U.S. Drug Market

Sept. 9, 2019, 11:00 AM

Drug companies have much at stake in a long-running antitrust case in which Chinese vitamin C exporters are accused of conspiring to fix prices and control the U.S. supply. The Second Circuit could rule any day now in an antitrust case remanded to it from the U.S. Supreme Court with instructions to give less deference to Chinese law. A loss for Chinese vitamin C companies could encourage similar suits from U.S. companies challenging market dominance practices.

C Is for China: Vitamin C may not be a drug, but a win for Chinese manufacturers in this case could give China the ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.